Well before Roche said it would buy out its CAR-T partner Poseida Therapeutics for $1 billion upfront, another undisclosed pharma company had sent the cell and gene therapy maker an unsolicited acquisition proposal. At the time of that proposal in April 2023, Poseida’s then-CEO Mark Gergen reached out to Roche’s then-global head of partnering, James Sabry, to see if Roche would be interested in a takeover. The Swiss pharma giant wasn’t intrigued, Sabry told him, but maybe it would consider an expansion of their collaboration and a subsequent acquisition in the future, according to new SEC filings outlining the background of the deal announced last month.
Read the full article: Roche Initially Didn’t Want to Buy Poseida — And Partner Astellas Didn’t Submit an Offer, New Filings Show //
Source: https://endpts.com/roche-initially-didnt-want-to-buy-poseida-and-partner-astellas-didnt-submit-an-offer-new-filings-show/